Leveraging Immune Checkpoint Inhibitors to Target Multiple Tumor Microenvironment Cell Population

Time: 1:30 pm
day: Conference Day 2


  • Novel biological activity stimulates thrombospondin-1 expression to target myeloid and inflammatory cells in the TME via CD36 and CD47
  • Understand the influence of the TME and peripheral immune cells in GBM IO treatment
  • Discuss promising biomarkers for responses to immune checkpoint inhibitors